Susquehanna International Group, LLP Ascendis Pharma A/S Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $4.72 Million - $6.41 Million	41,800 Added 52.58%	121,300 $18.1 Million
Q2 2024 Aug 15, 2024	BUY	$121.07 - $153.67 $1.5 Million - $1.91 Million	12,400 Added 18.48%	79,500 $10.8 Million
Q1 2024 May 07, 2024	SELL	$123.45 - $159.4 $1.41 Million - $1.82 Million	-11,400 Reduced 14.52%	67,100 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $3.79 Million - $5.6 Million	44,000 Added 127.54%	78,500 $9.89 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $1.99 Million - $2.39 Million	-23,000 Reduced 40.0%	34,500 $3.23 Million
Q2 2023 Aug 11, 2023	SELL	$69.96 - $97.84 $15.5 Million - $21.7 Million	-222,100 Reduced 79.43%	57,500 $5.13 Million
Q1 2023 May 16, 2023	BUY	$104.9 - $126.78 $13.2 Million - $15.9 Million	125,400 Added 81.32%	279,600 $30 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $12.4 Million - $16.5 Million	125,200 Added 431.72%	154,200 $18.8 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $5.56 Million - $7.3 Million	-66,200 Reduced 69.54%	29,000 $3 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $1.06 Million - $1.6 Million	13,600 Added 16.67%	95,200 $8.85 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $7.41 Million - $9.84 Million	72,500 Added 796.7%	81,600 $9.58 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $2.4 Million - $3.21 Million	-18,900 Reduced 67.5%	9,100 $1.22 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $980,229 - $1.54 Million	-8,700 Reduced 23.71%	28,000 $4.46 Million
Q2 2021 Aug 11, 2021	BUY	$121.62 - $145.29 $1.33 Million - $1.58 Million	10,900 Added 42.25%	36,700 $4.83 Million
Q1 2021 May 17, 2021	BUY	$124.92 - $173.33 $2.3 Million - $3.19 Million	18,400 Added 248.65%	25,800 $3.33 Million
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $3.33 Million - $4.02 Million	-22,000 Reduced 74.83%	7,400 $1.23 Million
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $11.6 Million - $13.4 Million	-86,600 Reduced 74.66%	29,400 $4.54 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $3.79 Million - $5.34 Million	34,200 Added 41.81%	116,000 $17.2 Million
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $9.14 Million - $13.7 Million	-94,200 Reduced 53.52%	81,800 $9.21 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $20 Million - $30.5 Million	-218,900 Reduced 55.43%	176,000 $24.5 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $4.51 Million - $5.6 Million	-47,100 Reduced 10.66%	394,900 $38 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $39.9 Million - $49.2 Million	-372,600 Reduced 45.74%	442,000 $50.9 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $24 Million - $50.2 Million	386,400 Added 90.24%	814,600 $95.9 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $21.7 Million - $27.4 Million	393,700 Added 1141.16%	428,200 $26.8 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $242,326 - $289,864	3,800 Added 12.38%	34,500 $2.45 Million
Q2 2018 Aug 14, 2018	BUY	$58.55 - $73.92 $1.8 Million - $2.27 Million	30,700 New	30,700 $2.04 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

Ra Capital Management, L.P. Boston, MA

9.71M
Shares

$1.32 Billion
20.22% of portfolio
Westfield Capital Management CO LP Boston, MA

5.13M
Shares

$700 Million
3.62% of portfolio
Avoro Capital Advisors LLC New York, NY

4.99M
Shares

$680 Million
11.21% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

4.41M
Shares

$602 Million
1.03% of portfolio
Janus Henderson Group PLC London, X0

4.19M
Shares

$571 Million
0.33% of portfolio

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account